• To estimate the cost-effectiveness of delayed-release dimethyl fumarate compared with glatiramer acetate and fi ngolimod in treatment of relapsing-remitting multiple sclerosis (RRMS) in the United States (US).
• A cohort-based Markov model tracking patients through EDSS health states with a cycle time of 1 year was developed in Microsoft Excel. Each year patients can transition to better or worse EDSS health states, have a relapse, transition from RRMS to secondary progressive multiple sclerosis (SPMS), and/or die. Disease-modifying treatment (DMT) was assumed to reduce the rate of EDSS progression and the annual relapse rate but not the rate of transition from RRMS to SPMS (Figure 1 ).
• Annual discontinuation rates were assumed to be the same for all DMTs (10% in years 1 and 2 and 3% in all subsequent years). All patients were assumed to stop DMT when their EDSS level reached 7.
• The model was designed to estimate the discounted (at 3%) cost and quality-adjusted life-years (QALYs) associated with treatment with delayed-release dimethyl fumarate compared with glatiramer acetate or fi ngolimod in RRMS.
• Population characteristics matched those in the delayed-release dimethyl fumarate phase 3 clinical trials (Table 1 ).
• The untreated rate of transition between the EDSS health states and annualized relapse rates were estimated using data from the placebo arms of the phase 3 clinical trials.
• The extent to which the DMTs slowed disease progression and reduced annualized relapse rates was estimated using a mixed-treatment comparison (MTC) analysis (Table 2) . • Costs included drug acquisition costs (wholesale acquisition costs [WACs]), administration and monitoring costs (based on resource use estimates and US unit costs), and the cost and disutility associated with adverse events (based on adverse event rates, resource use for treatment of adverse events, disutility for each serious and nonserious adverse event, and US unit costs) ( Table 3 ).
OBJECTIVE
• Cost and patient utility in each EDSS health state were based on published US data (Table 4) . b Administration and monitoring costs for each DMT were estimated using resource use assumed to be needed to train and monitor self-administration for the injectable drugs, as well as to monitor for effi cacy and safety through physician visits and laboratory tests as recommended in the product prescribing information; standard US unit costs were applied to the resource use estimates. c Adverse event costs and QALY loss were estimated based on estimated incidence rates for each DMT for the most common adverse events observed in the delayed-release dimethyl fumarate clinical trials, percentage of those adverse events that were serious for each DMT, and resource use and disutility for each serious and nonserious adverse event based on expert opinion; standard US unit costs were applied to the resource use estimates.
• Results were presented for a 10-year time horizon.
• Compared with glatiramer acetate and fi ngolimod, delayed-release dimethyl fumarate increased QALYs by 0.205 and 0.156 QALYs, respectively, and was less costly by $9,879 and $16,462, respectively (Table 5 ).
• Thus, delayed-release dimethyl fumarate was dominant (had lower costs and higher QALYs gained) compared with glatiramer acetate and fi ngolimod (Table 5 ).
• Sensitivity analyses showed that delayed-release dimethyl fumarate was less costly and more effective than glatiramer acetate for most of the input parameter values and assumptions tested ( Figure 2 ).
• Sensitivity analyses for fi ngolimod also showed that delayed-release dimethyl fumarate was less costly and more effective for most of the input parameter values and assumptions tested. In particular, incremental costs were most sensitive to delayed-release dimethyl fumarate acquisition costs (+10% +$21,356; -10% -$54,280), including informal care costs and productivity losses (-$25,163), and using annual discontinuation rates from the MTC (-$36,630). QALYs were most sensitive to changes in delayed-release dimethyl fumarate impact on disease progression (Upper 95% CI -0.031; Lower 95% CI +0.304) and use of Kobelt utility values (+0.022). Note: QALYs in those with SPMS were assumed to be 0.0092 lower than for those with RRMS, and occurrence of a relapse during the year was assumed to reduce QALYs by 0.0437 for both those with RRMS and SPMS.
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RESULTS
Drug
Total b Delayed-release dimethyl fumarate is less costly and more effective (lower right quadrant in the cost-effectiveness plane).
• One-way sensitivity analyses were performed changing input parameter values and model assumptions. A.
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